New Launch18 Mar 2025, 12:18 am
Morepen Laboratories Launches Affordable Diabetes Treatment Empamore
AI Summary
Morepen Laboratories Limited has announced the launch of Empamore, a cost-effective treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). Empamore, manufactured in USFDA-approved facilities, offers high-quality treatment at an affordable price point, aiming to make a significant impact in India, the diabetes capital of the world. The product range includes Empagliflozin (Empamore 10mg/25mg) and Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg).
Key Highlights
- Launch of Empamore, a cost-effective treatment for T2DM, HFrEF, and CKD
- Manufactured in USFDA-approved facilities with European DMF
- Affordable pricing, nearly 90% lower than existing brands
- Aims to capture a significant share of the rapidly growing diabetes market in India
- Morepen's legacy in diabetes management solutions and commitment to empowering people with 'Health in Your Hands'